DCGI gives nod to Bharat Biotech to conduct phase I and II Human clinical trials to develop vaccine

DCGI gives nod to Bharat Biotech to conduct phase I and II Human clinical trials to develop vaccine

Mid-Day

Published

New Delhi: The Drug Controller General of India (DCGI) has granted permission to Bharat Biotech International Limited (BBIL) to conduct Phase I and II Human clinical trials to develop an indigenous vaccine for COVID-19 -- in the name COVAXIN.

For this, Indian Council of Medical Research (ICMR) and BBIL had partnered to develop...

Full Article